Learn how oncologists spot burnout early and cut it with smarter workflows, PTO coverage, supportive leadership, and ...
The OS findings follow the recent FDA approval of zanidatamab with or without tislelizumab in HER2-positive gastroesophageal cancer. Zanidatamab-hrii (Ziihera) plus chemotherapy demonstrated a ...
A type C meeting between IDEAYA Biosciences and the FDA has established the design of a phase 3 registrational trial for ...
A gynecologic oncologist unpacks shifting cancer trends, HRD and germline testing, screening pitfalls, and where new ...
August 2026 FDA oncology updates: iberdomide, zanidatamab and daraxonrasib win approvals as fast-track designations ...
The FDA has approved rusfertide (Mimrylo) for adult patients with polycythemia vera (PV). 1 ...
The FDA has approved ropeginterferon alfa-2b-njft (Besremi) for adults with essential thrombocythemia (ET), marking the first ...
ASCO's updated guideline on breast cancer follow-up recommends risk-based surveillance intensity and selective mammography ...
FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate ...
Survey of 200+ oncology physicians reveals top burnout drivers—EMR burden, leadership gaps, poor work-life boundaries, and ...
Varsetatug masetecan is a first-in-class ADC that pairs a monoclonal antibody against EpCAM with a topoisomerase 1 inhibitor ...
The recent FDA approval of iberdomide (Zenbexus) represents more than the approval of a single new drug for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results